Get 20M+ Full-Text Papers For Less Than $1.50/day. Start a 14-Day Trial for You or Your Team.

Learn More →

Hypertension in Continuous Ambulatory Peritoneal Dialysis Patients: What do we know and What can we do about It?

Hypertension in Continuous Ambulatory Peritoneal Dialysis Patients: What do we know and What can... Despite many advantages of CAPD in maintaining hemodynamic stability, approximately 50% -60% of CAPD patients have hypertension and require antihypertensive treatment. ACE inhibitors and betablockers are the preferred first-line antihypertensive drugs in these patients, but some patients may require additionallong-acting calcium antagonists to enhance antihypertensive effects. Despite antihypertensive treatment, many patients often fail to maintain BP within optimal ranges, and this fact may contribute to the high incidences of cardiovascular morbidity an d mortality. Vigilance is clearly desirable by the patient and the physician to maintain BP within target ranges most of the time. Because dialysis patients also have many other cardiovascular risk factors, the strategy to decrease cardiovascular mortality should be a combined effort targeting all potential risk factors at the same time. http://www.deepdyve.com/assets/images/DeepDyve-Logo-lg.png Peritoneal Dialysis International SAGE

Hypertension in Continuous Ambulatory Peritoneal Dialysis Patients: What do we know and What can we do about It?

Cheigh, Jhoong S.; Kim, Hyang
Peritoneal Dialysis International , Volume 19 (2_suppl): 6 – Feb 1, 1999
Download PDF
6 pages

Loading next page...
 
/lp/sage/hypertension-in-continuous-ambulatory-peritoneal-dialysis-patients-k00guGTgbG

References (39)

Publisher
SAGE
Copyright
© 1999 International Society for Peritoneal Dialysis
ISSN
0896-8608
eISSN
1718-4304
DOI
10.1177/089686089901902S22
Publisher site
See Article on Publisher Site

Abstract

Despite many advantages of CAPD in maintaining hemodynamic stability, approximately 50% -60% of CAPD patients have hypertension and require antihypertensive treatment. ACE inhibitors and betablockers are the preferred first-line antihypertensive drugs in these patients, but some patients may require additionallong-acting calcium antagonists to enhance antihypertensive effects. Despite antihypertensive treatment, many patients often fail to maintain BP within optimal ranges, and this fact may contribute to the high incidences of cardiovascular morbidity an d mortality. Vigilance is clearly desirable by the patient and the physician to maintain BP within target ranges most of the time. Because dialysis patients also have many other cardiovascular risk factors, the strategy to decrease cardiovascular mortality should be a combined effort targeting all potential risk factors at the same time.

Journal

Peritoneal Dialysis International – SAGE

Published: Feb 1, 1999

There are no references for this article.